Cardiff Q3: Onvansertib PFS Still Not Reached at 21+ Months; Phase 3 Slated for Q1 2027
CRDF is trading near its 52-week low of $0.72 (1.0% above the low).
Summary
Cardiff's Q3 release repeats the 10-Q financials but adds that median PFS is still not reached in the proposed Phase 3 regimen, with patients past 21 months on treatment, as it prepares a registrational trial for a potential Q1 2027 start.
Key Events · Earnings and Guidance · CRDF
-
Onvansertib PFS Still Not Reached
Median PFS has not been reached in the 30 mg onvansertib + FOLFIRI/bev arm, the proposed Phase 3 regimen, versus approximately 11 months in the combined standard-of-care arms.
-
Patients Past 21 Months on Treatment
All patients remaining in the 30 mg onvansertib + FOLFIRI/bev arm have exceeded 21 months on treatment, with the longest over 29 months; as of September 28, 2026, 6 patients remain on the FOLFIRI/bev regimen.
-
Phase 3 Start Targeted Q1 2027
Cardiff is preparing a registrational Phase 3 trial in first-line RAS-mutated mCRC, with a potential start in the first quarter of 2027.
-
Cash Runway to Q3 2027
As of September 30, 2026, cash, cash equivalents and short-term investments totaled $33.8 million, with $33.9 million of operating cash used in the first nine months; runway is stated to the end of Q3 2027.
Analysis · CRDF · Life Sciences
The financials here rehash the 10-Q filed hours earlier — $33.8M in cash, a $30.4M nine-month net loss, and runway to the end of Q3 2027. What is new is the clinical read: median PFS has still not been reached in the 30 mg onvansertib + FOLFIRI/bev arm versus roughly 11 months for standard of care, and every patient left in that arm has passed 21 months on treatment. For a company trading near its 52-week low with going-concern doubt, that separation is the entire investment case, and management now points to a registrational Phase 3 start as early as Q1 2027. The catch is funding: the Phase 3 will need capital the current $33.8M does not cover, so a raise is the likely next step.
How filings like this one have moved
In the 30 days to Nov 12, 2026, 37% of the 3595 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CRDF was trading at $0.73 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $56.6M. The 52-week trading range was $0.72 to $3.31. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.